Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system (ImPrEP CAB Brasil): a hybrid type-2 implementation-effectiveness cohort study
Article by ImPrEP published in August 2026 ate The Lancet HIV.
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00201-8/fulltext